ReviewImmunological reviews2008
Antigen-specific immunotherapy of cervical and ovarian cancer.
Review in Immunological reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 65 citations in OpenAlex.
- Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.Journal for immunotherapy of cancer · 2020Trial
- Single-cell and spatial transcriptomic profiling reveals distinct tumor microenvironment dynamics in cervical adenocarcinoma and squamous cell carcinoma.Communications biology · 2025Article
- Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives.Medical oncology (Northwood, London, England) · 2024Review
- HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective.Virusdisease · 2023Review
- Article
- Ovarian Microbiota, Ovarian Cancer and the Underestimated Role of HPV.International journal of molecular sciences · 2022Article
- Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors.Cancer immunology, immunotherapy : CII · 2021Article
- A Comprehensive in Silico Analysis for Identification of Immunotherapeutic Epitopes of HPV-18.International journal of peptide research and therapeutics · 2021Article
- Therapeutic Vaccines for HPV-Associated Malignancies.ImmunoTargets and therapy · 2020Review
- Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma.Nature communications · 2019Observational
- Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.International journal of molecular sciences · 2019Review
- Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer.International journal of radiation oncology, biology, physics · 2018Observational
- Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.Expert review of vaccines · 2016Review
- Adoptive immunotherapy against ovarian cancer.Journal of ovarian research · 2016Review
- Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.Gynecologic oncology · 2016Review
- Article
- Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.Oncotarget · 2015Article
- Past, present and future targets for immunotherapy in ovarian cancer.Immunotherapy · 2014Review
- In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.Cancer science · 2014Article
- Immunotherapy for ovarian cancer: what's next?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We contrast the efforts to treat ovarian cancer and cervical cancer through vaccination because of their different pathobiology. A plethora of approaches have been developed for therapeutic vaccination against cancer, many of which target defined tumor-associated antigens (TAAs). Persistent infection with oncogenic human papillomavirus (HPV) types causes cervical cancer. Furthermore, cervical cancer patients frequently mount both humoral and T-cell immune responses to the HPV E6 and E7 oncoproteins, whose expression is required for the transformed phenotype. Numerous vaccine studies target these viral TAAs, including recent trials that may enhance clearance of pre-malignant disease. By contrast, little is known about the etiology of epithelial ovarian cancer. Although it is clear that p53 mutation or loss is a critical early event in the development of epithelial ovarian cancer, no precursor lesion has been described for the most common serous histotype, and even the location of its origin is debated. These issues have complicated the selection of appropriate ovarian TAAs and the design of vaccines. Here we focus on mesothelin as a promising ovarian TAA, because it is overexpressed and immunogenic at high frequency in patients, is displayed on the cell surface, and potentially contributes to ovarian cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.